Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATOS NASDAQ:CDT NASDAQ:RLYB NASDAQ:XLO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATOSAtossa Genetics$5.60-1.2%$5.18$3.76▼$19.35$48.83M1.2561,457 shs31,395 shsCDTCDT Equity$2.01-3.4%$8.50$1.96▼$1,312.50$10.11M1.682,052 shs36,620 shsRLYBRallybio$14.38-1.9%$9.18$2.16▼$15.31$77.55M-1.1621,834 shs89,292 shsXLOXilio Therapeutics$7.74-0.9%$8.05$6.47▼$16.52$46.73M-0.1632,812 shs22,946 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATOSAtossa Genetics-2.24%+5.59%+16.19%+6.18%-53.39%CDTCDT Equity-7.96%-10.73%-50.71%-92.57%-99.83%RLYBRallybio+0.69%+63.25%+82.11%+208.63%+509.61%XLOXilio Therapeutics-1.14%-1.39%-8.12%+3.13%-16.30%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATOSAtossa Genetics$5.60-1.2%$5.18$3.76▼$19.35$48.83M1.2561,457 shs31,395 shsCDTCDT Equity$2.01-3.4%$8.50$1.96▼$1,312.50$10.11M1.682,052 shs36,620 shsRLYBRallybio$14.38-1.9%$9.18$2.16▼$15.31$77.55M-1.1621,834 shs89,292 shsXLOXilio Therapeutics$7.74-0.9%$8.05$6.47▼$16.52$46.73M-0.1632,812 shs22,946 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATOSAtossa Genetics-2.24%+5.59%+16.19%+6.18%-53.39%CDTCDT Equity-7.96%-10.73%-50.71%-92.57%-99.83%RLYBRallybio+0.69%+63.25%+82.11%+208.63%+509.61%XLOXilio Therapeutics-1.14%-1.39%-8.12%+3.13%-16.30%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATOSAtossa Genetics 2.40Hold$36.33548.81% UpsideCDTCDT Equity 1.00SellN/AN/ARLYBRallybio 1.00SellN/AN/AXLOXilio Therapeutics 2.50Moderate Buy$28.00261.76% UpsideCurrent Analyst Ratings BreakdownLatest CDT, ATOS, RLYB, and XLO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/20/2026ATOSAtossa Genetics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/10/2026ATOSAtossa Genetics Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$120.00 ➝ $24.003/27/2026CDTCDT Equity Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/26/2026ATOSAtossa Genetics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$25.00(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATOSAtossa GeneticsN/AN/AN/AN/A$4.57 per shareN/ACDTCDT EquityN/AN/AN/AN/A($77.82) per shareN/ARLYBRallybio$860K88.45N/AN/A$10.98 per share1.31XLOXilio Therapeutics$43.77M1.06N/AN/A$7.31 per share1.06Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATOSAtossa Genetics-$34.77M-$3.60N/AN/AN/AN/A-65.56%-57.74%5/8/2026 (Estimated)CDTCDT Equity-$39.22M-$66,338.55N/AN/AN/AN/A-4,263.33%-529.91%N/ARLYBRallybio-$8.98M-$2.56N/AN/AN/A-1,046.39%-56.93%-52.67%5/12/2026 (Estimated)XLOXilio Therapeutics-$35.04M-$5.49N/A21.50N/A-80.05%-393.01%-33.59%5/14/2026 (Estimated)Latest CDT, ATOS, RLYB, and XLO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026XLOXilio Therapeutics-$0.66N/AN/AN/A$8.52 millionN/A5/12/2026Q1 2026RLYBRallybio-$1.20N/AN/AN/A$0.23 millionN/A5/8/2026Q1 2026ATOSAtossa Genetics-$0.99-$1.11-$0.12-$1.11N/AN/A3/23/2026Q4 2025XLOXilio Therapeutics-$1.68-$0.85+$0.83$0.81$10.90 million$13.69 million3/16/2026Q4 2025RLYBRallybio-$1.04-$1.03+$0.01-$1.03$0.10 million$0.22 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthATOSAtossa GeneticsN/AN/AN/AN/AN/ACDTCDT EquityN/AN/AN/AN/AN/ARLYBRallybioN/AN/AN/AN/AN/AXLOXilio TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATOSAtossa GeneticsN/A5.535.53CDTCDT EquityN/A0.340.34RLYBRallybioN/A14.5114.50XLOXilio TherapeuticsN/A2.582.58Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATOSAtossa Genetics12.74%CDTCDT Equity3.29%RLYBRallybio90.34%XLOXilio Therapeutics54.29%Insider OwnershipCompanyInsider OwnershipATOSAtossa Genetics9.80%CDTCDT Equity10.78%RLYBRallybio10.30%XLOXilio Therapeutics8.96%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATOSAtossa Genetics88.61 million7.77 millionOptionableCDTCDT Equity34.86 million4.33 millionNot OptionableRLYBRallybio405.29 million4.75 millionNot OptionableXLOXilio Therapeutics705.98 million5.45 millionNot OptionableCDT, ATOS, RLYB, and XLO HeadlinesRecent News About These CompaniesXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 7 at 4:30 PM | globenewswire.comXilio Therapeutics (XLO) Expected to Announce Earnings on ThursdayMay 7 at 4:07 AM | americanbankingnews.comXilio Therapeutics (NASDAQ:XLO) Trading Up 5.1% - Time to Buy?May 2, 2026 | americanbankingnews.comXilio Therapeutics (XLO) price target decreased by 28.57% to 20.40April 28, 2026 | msn.comXilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2April 17, 2026 | globenewswire.comXilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of DirectorsApril 16, 2026 | markets.businessinsider.comXilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D.April 16, 2026 | globenewswire.comXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 3, 2026 | globenewswire.comXilio Therapeutics (XLO) Upgraded to Buy: What Does It Mean for the Stock?April 1, 2026 | zacks.comXilio Therapeutics (XLO) price target increased by 1,300.00% to 28.56March 28, 2026 | msn.comCancer Stocks to Buy as Innovation Reshapes Global Oncology MarketMarch 26, 2026 | zacks.comXilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2025 Financial ResultsMarch 23, 2026 | globenewswire.comXilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program Targeting CLDN18.2 at the American Association for Cancer Research (AACR) Annual MeetingMarch 17, 2026 | globenewswire.comXilio Therapeutics Announces 1-for-14 Reverse Stock SplitMarch 12, 2026 | globenewswire.comXilio Therapeutics to Present at the Leerink Partners Global Healthcare ConferenceMarch 2, 2026 | globenewswire.comXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 2, 2026 | globenewswire.comXilio Therapeutics Shareholders Approve Flexible Reverse Stock SplitFebruary 24, 2026 | tipranks.comXilio Therapeutics Announces Pricing of Underwritten OfferingFebruary 11, 2026 | globenewswire.comXilio Therapeutics Announces Leadership Transition and Pipeline UpdatesJanuary 20, 2026 | theglobeandmail.comXilio Therapeutics, Inc.: Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate UpdatesJanuary 8, 2026 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWith Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?By Sam Quirke | April 12, 20263 Dividend Aristocrats Whose Yields Can Help Combat InflationBy Chris Markoch | April 9, 20265 Stocks Positioned to Win the AI Data Center BuildoutBy Bridget Bennett | April 20, 2026The Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 2026Defense Budget Expansion: 3 Mid-Cap Names in a Sweet Spot By Chris Markoch | April 20, 2026CDT, ATOS, RLYB, and XLO Company DescriptionsAtossa Genetics NASDAQ:ATOS$5.60 -0.07 (-1.23%) Closing price 04:00 PM EasternExtended Trading$5.42 -0.18 (-3.21%) As of 07:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.CDT Equity NASDAQ:CDT$2.01 -0.07 (-3.37%) Closing price 03:58 PM EasternExtended Trading$2.06 +0.05 (+2.24%) As of 06:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.Rallybio NASDAQ:RLYB$14.38 -0.28 (-1.91%) Closing price 04:00 PM EasternExtended Trading$14.40 +0.02 (+0.14%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.Xilio Therapeutics NASDAQ:XLO$7.74 -0.07 (-0.90%) Closing price 04:00 PM EasternExtended Trading$7.94 +0.21 (+2.65%) As of 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
